Sotera Health Company (NASDAQ:SHC – Get Free Report) Chairman Michael Jr. Petras sold 850,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the transaction, the chairman owned 3,969,393 shares in the company, valued at $73,433,770.50. This trade represents a 17.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Sotera Health Stock Performance
Shares of NASDAQ:SHC traded up $0.49 on Wednesday, hitting $19.00. The company had a trading volume of 2,683,334 shares, compared to its average volume of 2,901,701. The stock has a 50 day moving average price of $17.59 and a 200 day moving average price of $16.32. The stock has a market cap of $5.42 billion, a price-to-earnings ratio of 33.33 and a beta of 1.77. The company has a current ratio of 2.80, a quick ratio of 2.55 and a debt-to-equity ratio of 3.33. Sotera Health Company has a 1-year low of $13.09 and a 1-year high of $19.85.
Sotera Health (NASDAQ:SHC – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The firm had revenue of $321.38 million during the quarter, compared to analyst estimates of $309.70 million. During the same quarter last year, the business posted $0.20 EPS. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Analysts expect that Sotera Health Company will post 0.87 EPS for the current year.
Hedge Funds Weigh In On Sotera Health
Analyst Upgrades and Downgrades
A number of research firms have commented on SHC. UBS Group set a $19.00 target price on Sotera Health in a report on Wednesday, June 24th. Weiss Ratings raised Sotera Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Barclays boosted their price objective on Sotera Health from $19.00 to $22.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. JPMorgan Chase & Co. raised their target price on shares of Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, Citigroup increased their price target on Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.50.
Check Out Our Latest Analysis on SHC
Sotera Health Company Profile
Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.
Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.
Recommended Stories
- Five stocks we like better than Sotera Health
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
